AUSTIN, Texas — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company today announced that Marra Francis, MD has been appointed to the position of Chief Medical Officer as of November 8th.
Dr. Francis is a board certified Obstetrician and Gynecologist with over 13 years of clinical experience in both Private Practice and the Women’s Health diagnostics industry. Her previous experience includes the following: a National Speaker and Key Opinion Leader for Myriad Genetics, Inc., National Speaker for Cord Blood Registries, an “Ask the Expert” at Parents.com, a contributing physician to the “Mommy MD Guide” books and publications, and a medical affairs consultant for Vermillion prior to accepting the Chief Medical Officer role. Dr. Francis’ clinical practice over the years has ranged from general Obstetrician/Gynecologist to Gynecology only with a specialized focus on high risk cancer patients. She currently maintains a clinical practice in San Antonio with Women’s Health Consultants. Dr. Francis has presented hundreds of education programs around the country teaching her peers about the importance of hereditary cancer genetic testing, cord blood banking, and the best clinical care pathway of the adnexal mass, including CME Programs, Grand Rounds, National Society Meeting Programs, and Risk Management Conferences. She has also published on the best clinical practice for evaluating cancer risks in the Ob/Gyn practice, and on the role of interleukins in both breast and pancreatic cancer. Dr. Francis served as both Vice Chair and Chair of the Department of Obstetrics and Gynecology at Memorial Hermann The Woodlands Hospital.
“We are very pleased to have Marra join our organization,” stated Valerie Palmieri, President and CEO of Vermillion. “Her core expertise in understanding critical women’s health issues and high risk gynecology will be an asset to our company. Marra will be supporting our march for additional guideline and payer coverage as well as educating practice Gynecologists on the overall adoption of our technology. In addition, due to being a practicing Gyn, her skill set will be instrumental to developing new technologies that aid the patient, physician, and payer and can be well integrated into practice.”
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with debilitating diseases. The company’s initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity and ease of use and which uses widely distributed platforms. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
LifeSci Advisors LLC